Boston: Zenas BioPharma, Inc. (‘Zenas’ or the ‘Company’) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company, has announced its 2024 accomplishments, outlined key business objectives for 2025, and shared a preliminary unaudited cash balance as of the year-end 2024. The company remains committed to leading the development and commercialization of therapies for autoimmune diseases.

According to BERNAMA News Agency, Zenas BioPharma’s Founder and Chief Executive Officer, Lonnie Moulder, highlighted the progress made across all corporate goals in 2024, which positions the company to achieve significant milestones in 2025. The anticipated outcomes from the ongoing obexelimab Phase 2 and Phase 3 clinical trials are expected to drive major value. Moulder expressed pride in the team’s achievements and noted that the company is well-financed to focus on execution and the achievement of key objectives in the coming year.